Diverse therapeutic device company focused on the development of new treatments for cardiovascular diseases
Orchestra BioMed (OBIO) is a therapeutic device company focused on the development and commercialization of high impact, data-driven, transformational solutions for targeted high value unmet medical needs. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year or 31% of all global deaths according to the World Health Organization.
OBIO was formed primarily through the combination of Caliber Therapeutics, Inc., BackBeat Medical, Inc. and other therapeutic device assets founded and developed by the principals of Orchestra Medical Ventures
Organized around pipeline of late-stage transformational cardiovascular therapies with strong clinical data addressing specific high-need patient populations with artery disease and hypertension:
Cardiovascular Interventions: focused on the development of transformational technologies in the field of interventional cardiology with Virtue® Sirolimus-Eluting Balloon (SEB) as its lead product
Cardiac Neuromodulation: focused on the development of transformational bioelectric therapies primarily for the treatment of hypertension with BackBeat® Cardiac Neuromodulation Therapy (CNT) as the lead product
Strategic Innovations: responsible for creating additional shareholder value through ownership, investment in, acquisition of, and strategic advisory services to additional therapeutic device assets with initial ownership positions that include one wholly-owned subsidiary (FreeHold Surgical®) and two large minority interests in other therapeutic device companies (Motus GI®, Vivasure® Medical.)
Leverages senior management, board, advisory, finance, clinical, regulatory, and marketing resources across business units to enhancing operational and capital efficiency